XML 18 R6.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Cash flows from operating activities              
Net loss $ (1,793,774) $ (2,027,579) $ (2,045,223) $ (2,009,596) $ (3,821,353) $ (4,054,819)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Stock-based compensation expense 340,462   297,603   565,492 604,081  
Amortization of held-to-maturity securities, net         (15,996) (27,699)  
Amortization of debt issuance costs         23,794 26,717  
Gain from the sale of investment in Alphazyme     (60,977)  
Foreign currency exchange loss (gain), net         23,170 8,049  
Changes in operating assets and liabilities:              
Interest receivable         (10,488) (18,077)  
Accounts receivable         (471,860) 210,725  
Prepaid expenses and other current assets         218,050 201,073  
Operating lease assets and liabilities         11 870  
Accounts payable         224,080 (224,307)  
Accrued expenses         191,009 152,800  
Accrued interest         80,000  
Accrued interest - related party         (5,373) 32,000  
Deferred research and development obligation         999,718 (7,790)  
Net cash used in operating activities         (2,079,746) (3,077,354)  
Cash flows from investing activities              
Purchases of held-to-maturity investment securities         (4,560,278) (4,734,528)  
Proceeds from maturities of investment securities         4,080,762 1,546,000  
Proceeds from the sale of investment in Alphazyme         60,977  
Net cash used in investing activities         (479,516) (3,127,551)  
Cash flows from financing activities              
Proceeds from exercise of stock         24,249  
Proceeds from issuance of convertible notes, net of issuance costs         3,882,884  
Proceeds from issuance of convertible notes, net of issuance costs - related party         1,941,442  
Net cash provided by financing activities         24,249 5,824,326  
Effect of exchange rate changes on cash         2,693 (1,051)  
Net decrease in cash, cash equivalents, and restricted cash and cash equivalents         (2,532,320) (381,630)  
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period   $ 6,506,750   $ 6,515,028 6,506,750 6,515,028 $ 6,515,028
Cash, cash equivalents, and restricted cash and cash equivalents at end of period 3,974,430   6,133,398   3,974,430 6,133,398 6,506,750
Reconciliation of cash, cash equivalents, and restricted cash and cash equivalents to the consolidated balance sheets              
Cash and cash equivalents 2,140,899   6,133,398   2,140,899 6,133,398 6,506,750
Restricted cash and cash equivalents, current 1,588,384     1,588,384
Restricted cash and cash equivalents, noncurrent 245,147     245,147
Total cash, cash equivalents, and restricted cash and cash equivalents $ 3,974,430   $ 6,133,398   3,974,430 6,133,398  
Supplemental cash flow information              
Vesting of restricted stock units         269,100 439,085  
Conversion of convertible notes         400,000  
Cash paid for interest         $ 208,973 $ 34,844